|
業務類別
|
Biotechnology |
|
業務概覽
|
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action. |
| 公司地址
| 4800 Montgomery Lane, Suite 220, Bethesda, MD, USA, 20814 |
| 電話號碼
| +1 301 500-1556 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.gaintherapeutics.com |
| 員工數量
| 21 |
| Mr. Gianluca Fuggetta |
Senior Vice President, Finance, Principal Financial Officer and Principal Accounting Officer |
美元 241.35K |
28/04/2026 |
| Mr. Gene Mack |
Director, Chief Executive Officer and President |
美元 500.00K |
28/04/2026 |
|
|
| Dr. Dov A. Goldstein, M.B.A.,M.D. |
Independent Director |
28/04/2026 |
| Mr. Hans Peter Hasler |
Independent Director |
28/04/2026 |
| Dr. Claude Nicaise,M.D. |
Independent Director |
28/04/2026 |
| Dr. Khalid Islam, PhD |
Executive Chairman of the Board |
28/04/2026 |
| Ms. Gwen A. Melincoff |
Independent Director |
28/04/2026 |
| Mr. Jeffrey Riley |
Independent Director |
28/04/2026 |
| Mr. Gene Mack |
Director, Chief Executive Officer and President |
28/04/2026 |
|
|
|
|
